Know where your pharma services platform
actually stands on AI.
A 2-minute self-assessment that benchmarks your clinical data infrastructure and AI maturity against peer CROs and pharma services firms. Instant score. Actionable report. No sales call required to get it.
Five dimensions.
One composite score.
The AI Readiness Quotient evaluates the building blocks every pharma services firm needs to deploy production-grade AI — from clinical data standards to organizational alignment.
CDISC/SDTM compliance, multi-source data integration, and clinical data management maturity.
Site selection, enrollment forecasting, and clinical trial monitoring automation.
ML in biostatistics workflows, pharmacovigilance AI, and real-world evidence generation.
21 CFR Part 11 automation, eCTD assembly, and AI-powered regulatory intelligence.
Data science team structure, clinical operations integration, and leadership alignment.
Three steps.
Under two minutes.
Built for CTOs, VPs of Data Science, and Heads of Bioinformatics who know their stack. Every question is answerable in under 10 seconds.
One question at a time. Multiple choice. Each option describes a real state of clinical data and AI infrastructure we see across pharma services firms.
Composite score from 0–100 with tier label and dimension-level breakdown benchmarked against peer CROs and pharma services firms.
3 prioritized recommendations with quantified expected impact. Something you can bring to your leadership team or share with sponsors.
The gap between “we have AI”
and “AI accelerates our trials” is measurable.
Sponsors are demanding AI-driven trial execution. The CROs pulling ahead aren’t just investing in AI — they’re building the validated infrastructure to deploy it in production with regulatory confidence.
CROs with mature AI infrastructure are compressing trial timelines by 30–40%. That’s a structural advantage in sponsor win rates and pricing that compounds with every study.
Production AI requires validated pipelines, regulatory-grade audit trails, and operational integration. The score tells you exactly where your gaps are before you invest six figures finding out.
Based on our benchmark dataset. Most firms are in the “Building” tier — strong in one or two dimensions, with significant gaps elsewhere. Knowing which is the first step.
Production data systems for pharma and life sciences.
- Deep pharma and life sciences data expertise: clinical data pipelines, biostatistics workflows, and regulatory-grade infrastructure.
- Experience across CROs, CDMOs, and pharma services firms — we understand the sponsor relationship and the operational pressures.
- Our benchmark data comes from real engagements, not surveys. We know what good looks like at firms managing Phase I–IV trials.
- Outcome-aligned engagement model: our revenue is tied to the results we deliver, not the hours we bill.
FAQ
What is the Pharma Services AI Readiness Assessment?
The Pharma Services AIRQ (AI Readiness Quotient) is a 2-minute, 10-question self-assessment for CROs, CDMOs, and pharma services organizations. It scores your organization across five dimensions — Clinical Data Infrastructure, Trial Analytics & Automation, Biostatistics & ML, Regulatory & Compliance AI, and Org & Talent — producing a composite score from 0–100 benchmarked against 75+ peer firms.
Who is this assessment designed for?
This assessment is designed for CTOs, VP Data Science, Heads of Bioinformatics, and data leaders at CROs and pharma services firms who want to objectively benchmark their AI infrastructure against peers and identify the highest-impact gaps to close before investing further in AI initiatives.
How does this relate to CDISC/SDTM clinical data standards?
The Clinical Data Infrastructure dimension specifically evaluates your CDISC/SDTM compliance maturity, automated data transformation capabilities, and multi-source clinical data integration. Firms with mature CDISC automation consistently score higher and see faster study startup times.
Does this assessment address 21 CFR Part 11 compliance?
Yes. The Regulatory & Compliance AI dimension evaluates your Part 11 compliance automation, electronic audit trail maturity, and regulatory submission capabilities. We assess whether compliance is document-based (manual) or embedded continuously in your data platform.
How are scores calculated and what do they measure?
Scores are calculated across five weighted dimensions: Clinical Data Infrastructure (25%), Trial Analytics & Automation (25%), Biostatistics & ML (20%), Regulatory & Compliance AI (20%), and Org & Talent (10%). Your composite score is normalized to a 0–100 scale and compared against benchmark data from 75+ pharma services firms.
Can this help with sponsor conversations about AI capabilities?
Yes. The PDF report with dimension-level benchmarks and prioritized recommendations is designed to be shareable. Many firms use their AIRQ results to demonstrate AI maturity to sponsors or to build an internal business case for AI investment with quantified expected impact.
What does a good score look like for a pharma services firm?
The average score across pharma services firms in our benchmark dataset is 29, placing most firms in the “Building” tier. Scores above 61 are “Advanced” and above 81 are “Leading.” Most firms have strong performance in 1–2 dimensions and significant gaps in others.
Where can I download the State of AI in Pharma Services & CRO 2026 report?
The State of AI in Pharma Services & CRO 2026 (Q1 2026) is a free white paper published by Blue Orange Digital. It benchmarks clinical data infrastructure maturity, AI adoption, and technology investment priorities across 75+ pharma services firms. You can download it for free at https://blueorange.digital/pages/pharma-services/ — no form or sales call required.
State of AI in Pharma Services & CRO 2026
Our Q1 2026 benchmark report analyzes clinical data infrastructure maturity, AI adoption patterns, and technology investment priorities across 75+ pharma services firms and CROs. Includes dimension-level benchmarks, tier distributions, and the top initiatives firms are prioritizing this year.
- Average AIRQ scores by firm size and therapeutic area focus
- The 3 dimensions where pharma services firms are most underinvested
- What separates “Leading” firms from the middle tier
- AI adoption rates for trial automation, pharmacovigilance, and regulatory submissions
Benchmark your firm
in 2 minutes.
Walk away with a score, a peer comparison, and 3 prioritized recommendations. The full PDF report is yours immediately — no follow-up call required.
Get Your AI Readiness Score →